Product Description: Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599./[2]Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80(16_Supplement): 3260-3260.
CAS Number: 2256084-03-2
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: H2O
Target: PD-1/PD-L1